RESUMO
INTRODUCTION AND AIM: The gold-standard for fibrosis diagnosis in non-alcoholic fatty liver disease (NAFLD) is liver biopsy, despite its invasive approach, sampling limitations and variability among observers. The objective was to validate the performance of non-invasive methods (Fibroscan™; APRI, FIB4 and NAFLD score) comparing with liver biopsy in the evaluation of liver fibrosis in patients with NAFLD. MATERIAL AND METHODS: NAFLD patients ≥18 years of age who were submitted to liver biopsy were included and evaluated at two reference tertiary hospitals in Brazil with transient hepatic elastography (THE) assessment through Fibroscan™, APRI, FIB4 and NAFLD scores were determined. Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values for the diagnosis of advanced fibrosis were calculated to evaluate the performance of these non-invasive methods in NAFLD patients, adopting liver biopsy as the gold standard. RESULTS: A total of 104 patients were studied. At three different cutoff values (7.9, 8.7 and 9.6kPa) THE presented the highest sensitivity values (95%, 90% and 85% respectively), and the highest NPV (98%, 96.4% and 95.1% respectively) for the diagnosis of advanced fibrosis. It also presented the highest AUROC (0.87; CI 95% 0.78-0.97). CONCLUSION: When compared to the gold standard, transient hepatic elastography presented the best performance for the diagnosis and exclusion of advanced fibrosis in patients with NAFLD, overcoming APRI, FIB4 and NAFLD score.
Assuntos
Biópsia Guiada por Imagem/métodos , Cirrose Hepática/diagnóstico por imagem , Cirrose Hepática/epidemiologia , Hepatopatia Gordurosa não Alcoólica/diagnóstico por imagem , Hepatopatia Gordurosa não Alcoólica/epidemiologia , Adulto , Idoso , Área Sob a Curva , Brasil , Comorbidade , Estudos Transversais , Técnicas de Imagem por Elasticidade/métodos , Feminino , Humanos , Cirrose Hepática/patologia , Masculino , Pessoa de Meia-Idade , Hepatopatia Gordurosa não Alcoólica/patologia , Curva ROC , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Centros de Atenção Terciária , Ultrassonografia/métodosRESUMO
OBJECTIVES: To analyze the evolution of glomerular filtration rate (GFR) and the presence of renal tubular dysfunction during the treatment of chronic hepatitis B virus (HBV) infection with tenofovir disoproxil fumarate (TDF) and to determine the risk factors involved. METHODS: Retrospective cohort observational study of adults with chronic hepatitis B. Exclusion: hepatitis C virus-HBV coinfection, diabetes, baseline GFR less than 60â ml/min. Measurements of serum and urinary creatinine and phosphate; urinary albumin, retinol-binding protein (RBP) and neutrophil gelatinase-associated lipocalin (NGAL) were performed. Univariate and multivariate analyses tracked factors associated with worsening GFR. RESULTS: A total of 120 individuals were included: 35% NAÏVE (G1); 49.2% HBV using TDF (G2); 15.8% HBV-HIV using TDF (G3); 63.3% men; 60.8% white; 30% hypertensive. Average age was 50.5 years (SDâ ±â 12.9 years). Reactive HBeAg predominated in G3 ( P â <â 0.001) and cirrhosis in G2 ( P â <â 0.036). NGAL was elevated in 5.3% of cases (G1â =â 3.2%; G2â =â 8.7%; G3â =â 0%; P â =â 0.582), RBP in 6.7% (G1, G3â =â 0%; G2â =â 13.6%; P â =â 0.012), urinary phosphate/creatinine ratio in 16.2% (G1â =â 15.2%; G2â =â 14.5%; G3â =â 23.5%; P â =â 0.842) and urinary albumin/creatinine ratio in 12.9% (G1â =â 12.2%; G2â =â 10.7%; G3â =â 21.1%; P â =â 0.494). Worsening of renal function occurred in 22.5% of the population (G1â =â 11.9%; G2â =â 28.8%; G3â =â 26.3%; P â =â 0.122), independently associated only with systemic arterial hypertension [adjusted odds ratio (AOR)â =â 4.14; P â =â 0.008], but not to TDF (AORâ =â 2.66; P â =â 0.110) or male sex (AORâ =â 2.39; P â =â 0.135). However, the concomitance of these variables generated a high estimated risk for this outcome (51%). CONCLUSIONS: Renal tubular dysfunction was uncommon according to NGAL, RBP or urinary phosphate/creatinine ratio. TDF was not an independent factor for worsening renal function, significantly associated only with systemic arterial hypertension. However, in hypertensive men, the use of TDF should be monitored.